Seagen and astellas announce updated results from two trials of padcev® (enfortumab vedotin-ejfv) in patients with locally advanced or metastatic urothelial cancer not eligible for cisplatin chemotherapy

Bothell, wash. & tokyo--(business wire)-- #asco21--seagen inc. (nasdaq:sgen) and astellas pharma inc. (tse: 4503, president and ceo: kenji yasukawa, ph.d., “astellas”) today announced updated results from two clinical trials examining padcev® (enfortumab vedotin-ejfv) alone (ev-201 cohort 2) and padcev in combination with merck's (known as msd outside the united states and canada) keytruda® (pembrolizumab) (ev-103 cohort a) in patients with locally advanced or metastatic urothelial cancer who are not abl
SGEN Ratings Summary
SGEN Quant Ranking